Should Pharma Release IP For COVID-19 Research? Novartis Exec Weighs In

 
• By Brenda Sandburg
  
Patent Health Care Pharmaceuticals Innovation concept.
Intellectual property is central to COVID-19 innovation and collaboration, Novartis exec says

More from Legal & IP

More from Pink Sheet